Heterologous protection against Crimean-Congo hemorrhagic fever in mice after a single dose of replicon particle vaccine.

Abstract

No vaccines are currently licensed to prevent Crimean-Congo hemorrhagic fever virus (CCHFV) infection, which can cause mild self-limiting clinical signs or severe, often fatal hemorrhagic fever disease. Here we continued investigations into the utility of a single-dose virus replicon particle (VRP) vaccine regimen by assessing protection against Turkey or Oman strains of CCHFV. We found that all mice were completely protected from disease, supporting broad applicability of this platform for CCHFV prevention.

• Authors: Jessica R Spengler, Stephen R Welch, Florine E M Scholte, JoAnn D Coleman-McCray, Jessica R Harmon, Stuart T Nichol, Éric Bergeron, Christina F Spiropoulou
• Journal: Antiviral research (Antiviral Res) Vol. 170 Pg. 104573 (10 2019) ISSN: 1872-9096 [Electronic] Netherlands
• PMID: 31377243 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, U.S. Gov't, Non-P.H.S., Research Support, U.S. Gov't, P.H.S.)
• Copyright: Published by Elsevier B.V.

Chemical References

• Antibodies, Neutralizing
• Antibodies, Viral
• Viral Vaccines

Topics

• Animals
• Antibodies, Neutralizing (blood)
• Antibodies, Viral (blood)
• Disease Models, Animal
• Female
• Hemorrhagic Fever Virus, Crimean-Congo
• Hemorrhagic Fever, Crimean (immunology, prevention & control)
• Immunity, Heterologous
• Mice
• Replicon (immunology)
• Viral Vaccines (administration & dosage, immunology)
• Virion (immunology)